Davis Kelley

Davis Kelley is currently a Cell and Gene Therapy Associate PD Scientist at uBriGene Biosciences Inc. since March 2025. Prior experience includes roles as Associate Cell Scientist II and I at AstraZeneca from March 2023 to March 2025, where responsibilities involved maintaining cell sterility in a cGMP environment using aseptic techniques. From June 2020 to August 2021, internships at Johns Hopkins Medicine focused on analyzing skin diseases, contributing to research published in PubMed. Additionally, a Laboratory Assistant position at the University of Maryland involved studying the Rbfox1 gene's impact on Drosophila Melanogaster's innate immune response. Davis Kelley holds a Bachelor of Science in Bioengineering from the University of Maryland, obtained in May 2022.